๎๊ฒ์
๎๊ฒ์
๎
Pharvaris NV
PHVS๎ญ๊ด์ฌ ๋ชฉ๋ก์ ์ถ๊ฐ
33.360USD
-0.470-1.39%
์ข
๊ฐย 11-13 16:00๏ผET๏ผ
2.34B์๊ฐ์ด์ก
์์คP/E TTM
Pharvaris NV ์ ๋ณด ํ์ฌ
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
Pharvaris NV ํ๋กํ
๎์ข
๋ชฉ ์ฝ๋ PHVS
ํ์ฌ ์ด๋ฆPharvaris NV
์์ฅ์ผFeb 05, 2021
CEOModig (Berndt B.A.E)
์ง์ ์- -
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃFeb 05
์ฃผ์Emmy Noetherweg 2
๋์LEIDEN
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐNetherlands
์ฐํธ ๋ฒํธ2333 BK
์ ํ31712036410
์น์ฌ์ดํธhttps://pharvaris.com/
์ข
๋ชฉ ์ฝ๋ PHVS
์์ฅ์ผFeb 05, 2021
CEOModig (Berndt B.A.E)
Pharvaris NV์ ํ์ฌ ์์์ง
๎์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
549.79K
-0.04%
Dr. Anne Lesage, Ph.D.
Dr. Anne Lesage, Ph.D.
Co-Founder, Chief Early Development Officer
Co-Founder, Chief Early Development Officer
488.84K
--
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
185.12K
-3.51%
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
152.35K
+32.51%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
96.45K
--
Ms. Anna Nijdam
Ms. Anna Nijdam
Head of Finance, Principal Accounting Officer
Head of Finance, Principal Accounting Officer
47.61K
-5.61%
Mr. Berndt Modig, CPA
Mr. Berndt Modig, CPA
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
--
--
Dr. Jochen Knolle, Ph.D.
Dr. Jochen Knolle, Ph.D.
Co-Founder, Chief Operating Officer, Chief Scientific Officer
Co-Founder, Chief Operating Officer, Chief Scientific Officer
--
--
Dr. Morgan Conn, Ph.D.
Dr. Morgan Conn, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Mr. Hans Schikan, Pharm.D.
Mr. Hans Schikan, Pharm.D.
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
๋ ๋ณด๊ธฐ
์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
549.79K
-0.04%
Dr. Anne Lesage, Ph.D.
Dr. Anne Lesage, Ph.D.
Co-Founder, Chief Early Development Officer
Co-Founder, Chief Early Development Officer
488.84K
--
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
185.12K
-3.51%
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
152.35K
+32.51%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
96.45K
--
Ms. Anna Nijdam
Ms. Anna Nijdam
Head of Finance, Principal Accounting Officer
Head of Finance, Principal Accounting Officer
47.61K
-5.61%
์์ฃผ ๋ฌป๋ ์ง๋ฌธ
Pharvaris NV์ ์์ 5๋ ์ฃผ์ฃผ๋ ๋๊ตฌ์ธ๊ฐ์?
๎Pharvaris NV์ ์์ 5๋ ์ฃผ์ฃผ๋ ๋ค์๊ณผ ๊ฐ์ต๋๋ค: Dr. Peng Lu, M.D., Ph.D.
Pharvaris NV(PHVS)์ ์ฃผ์์ ๋ณด์ ํ ๊ธฐ๊ด์ ๋ช ๊ฐ์ ๋๊น?
๎2026Q1 ๊ธฐ์ค์ผ๋ก, Pharvaris NV์ ์ฃผ์์ ๋ณด์ ํ ๊ธฐ๊ด์ ์ด 165๊ณณ์ด๋ฉฐ, ์ด๋ค์ด ๋ณด์ ํ ์ฃผ์์ ์ด ๊ฐ์น๋ ์ฝ 59.26M๋ก ์ ์ฒด ๋ฐํ ์ฃผ์์ 90.60%๋ฅผ ์ฐจ์งํฉ๋๋ค. ์ด๋ 2025Q4 ๋๋น -451327.00 ์ฆ๊ฐํ ์์น์
๋๋ค.